Christopher R. Kelsey, MD, of Duke University Medical Center, discusses reducing the radiation dose from 30 Gy to 20 Gy for patients with diffuse large B-cell lymphoma. Phase II findings show this approach may be effective in light of improved systemic treatment and better chemotherapy response assessment (Presentation 298).
Jeffrey D. Bradley, MD, of Washington University School of Medicine, discusses long-term phase III findings on standard-dose vs high-dose conformal chemoradiation therapy with or w...
Marcus E. Randall, MD, of the University of Kentucky, discusses phase III study findings on pelvic radiation therapy vs vaginal cuff brachytherapy followed by paclitaxel/carboplati...
Bhishamjit S. Chera, MD, of the University of North Carolina, discusses quantification of human papillomavirus 16 in circulating tumor DNA during de-intensified chemoradiation ther...
Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session on NSCLC that included discussion of a quality-of-life trial on optimizing treatment; chemothe...
Juanita Crook, MD, of the University of British Columbia, discusses late toxicity findings on transperineal ultrasound–guided brachytherapy for locally recurrent prostate cancer af...